Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Sponsors of accelerated approval drugs must continue to submit promotional materials to FDA for review after their products reach the market, the agency indicated in its proposed regulation for accelerated approval published in the April 15 Federal Register. The agency noted that "because drugs approved under the restricted use provision [of the reg] may be highly toxic or otherwise potentially harmful, FDA is concerned that certain promotional claims could cause inappropriate and, therefore, unsafe use." FDA also expressed concern that inappropriate promotion could "readily" affect the risk/benefit ratio for drugs approved on the basis of surrogate endpoints. The extent of review will vary on a case-by-case basis. FDA does not intend specifically to approve promotional materials, the reg states, but only to require their submission. "Accordingly, the sponsor must submit promotional materials to FDA during the approval process and subsequent to approval," the reg states. Materials developed after approval must be submitted 30 days prior to dissemination. "Inappropriate" labeling or advertising could be cause for withdrawal of the NDA, the reg notes (see related story, p. 8).

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts